viningocouqyl1601.blogspot.com
The approval is the second such studyy authorization for the Radnor biotechnology company within the pastthree months. In May, PolyMedix received regulatory approval in Canad to begin human testing of itsantibiotiv compound, PMX-30063. The company started enrolling patients ina phase-kI safety trial for the antibiotic at the end of last PolyMedix, which is focused on developinfg new therapeutic drug products to treat infectious diseasezs and acute cardiovascular disorders based on is attempting to commercialize technology licensed from the . Biomimeticz are small molecule drugs which mimic the activitof proteins, but are inexpensive to make and formulat into drugs.
Nicholas Landekic , PolyMedix CEO, said PMX-60056 is in an entirely new class of drug the companhycalls heptagonists. PMX-60056 is designed to reversre the effectsof heparins, which are used after surgeryu and during cardiothoracic procedures, such as cardiac to prevent blood clots from forming. Existing drugzs used to turn off heparin activity have limitationzs that include difficulty inadjustingv doses, unpredictable efficacy, post-operative bleedingv complications and allergic reactions. “We are proud to be the first and only compangy to be developing this completely new typeof drug,” Landekivc said.
Exton-based signed a licensed agreement with the National Cancer Institutw for the rights to a monoclonal antibody for a novel antigen identified byNCI researchers. The company plans to develop the antibody as a potentiakl treatment for prostate Terms of the deal werenot
Subscribe to:
Post Comments (Atom)
Lindsay Rosenwald http://www.lindsayrosenwald.com/category/lindsay-rosenwald/ Dr. Lindsay Rosenwald is part of the Republican Jewish Coalition as a member of the Board of Directors.
ReplyDelete